Kyntra Bio (KYNB) FCF Margin (2014 - 2026)

Kyntra Bio has disclosed FCF Margin across 13 years of filings, most recently posting 270.76% for Q2 2026.

• In Q2 2026, FCF Margin fell 121060.0% year-over-year to 270.76%; the TTM figure through Jun 2026 stood at 503.13% (down 18056.0% YoY), while the FY2025 annual figure was 74.72%, up 39206.0% from the prior year.
• FCF Margin came in at 270.76% for Q2 2026 at Kyntra Bio, up from 371.51% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 939.84% in Q2 2025 to a low of 6876.42% in Q3 2024.
• Average FCF Margin over 5 years is 839.49%, with a median of 261.24% recorded in 2023.
• Year-over-year, FCF Margin slumped 666408 bps in 2024 and surged 670393 bps in 2025.
• Over 5 years, FCF Margin stood at 629.12% in 2022, then jumped by 104 bps to 25.16% in 2023, then tumbled by 3980 bps to 976.3% in 2024, then slumped by 47 bps to 1435.24% in 2025, then jumped by 81 bps to 270.76% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 270.76% in Q2 2026, 371.51% in Q1 2026, and 1435.24% in Q4 2025.